Eli Lilly's Combination Therapy Reveals Unexpected Synergistic Benefits

A novel dual-treatment approach from pharmaceutical giant Eli Lilly has demonstrated surprising efficacy in a recent clinical trial, achieving positive outcomes faster than anticipated. The findings from the TOGETHER-PsA study have the potential to redefine care standards for individuals suffering from both active psoriatic arthritis and obesity.

Financial Performance and Market Sentiment

Operationally, Eli Lilly continues to deliver robust results. The company's latest quarterly earnings reached $7.54 per share, surpassing the consensus estimate of $7.48. Quarterly revenue saw a substantial year-over-year increase of 42.6%, climbing to $19.29 billion. For the full 2026 fiscal year, management reaffirmed its earnings per share guidance in the range of $33.50 to $35.00.

Despite this strong operational backdrop, the equity's performance has recently diverged. Since the start of the year, the share price has declined by approximately 17%. Analyst confidence, however, remains firm. Morgan Stanley maintains an "Overweight" rating with a price target of $1,313, while Jefferies similarly recommends "Buy" with a $1,300 target.

Should investors sell immediately? Or is it worth buying Eli Lilly?

Deciphering the Clinical Trial Results

The TOGETHER-PsA study evaluated adults with active psoriatic arthritis and obesity, comparing a combination of Taltz (Ixekizumab) and Zepbound (Tirzepatide) against Taltz as a standalone therapy. The dual-treatment regimen successfully met all primary and key secondary endpoints, demonstrating statistically significant superiority.

A particularly notable finding emerged by week four. The combination group showed a greater reduction in disease activity, as measured by ACR50, at a point where clinically meaningful weight loss had not yet begun. This suggests a distinct synergistic effect between the two drugs that extends beyond the impact of weight reduction alone. Researchers highlight this as the first documented success of a dual-targeted approach for this specific patient population.

Upcoming Catalyst and Manufacturing Scale

Market attention now turns to a key regulatory date: April 10, 2026. On this day, the U.S. Food and Drug Administration (FDA) is scheduled to decide on the approval of Orforglipron. This experimental oral weight-loss drug would provide a non-injectable alternative to Zepbound, potentially significantly expanding the reach of the Tirzepatide franchise.

Demand for the company's existing products shows no signs of slowing. In the week ending March 20, 2026, approximately 729,600 Mounjaro and 608,600 Zepbound prescriptions were issued. To meet this sustained demand, Eli Lilly has invested roughly $55 billion since 2020 to expand its production capacity, aiming to achieve greater economies of scale and reduce unit costs over the long term.

Ad

Eli Lilly Stock: New Analysis - 29 March

Fresh Eli Lilly information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Eli Lilly analysis...

US5324571083 | ELI | boerse | 69020305 |